Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Setting occupational exposure limits for pharmaceuticals

B D Naumann1, E V Sargent

  • 1Merck & Co., Inc. Whitehouse Station, New Jersey 08889-0100, USA.

Occupational Medicine (Philadelphia, Pa.)
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The human relevant potency threshold: reducing uncertainty by human calibration of cumulative risk assessments.

Regulatory toxicology and pharmacology : RTP·2011
Same author

Guidelines for application of chemical-specific adjustment factors in dose/concentration-response assessment.

Toxicology·2002
Same author

Occupational hazard evaluation of p-bromobenzyl bromide from tests for genotoxicity.

Drug and chemical toxicology·1999
Same author

Performance-based exposure control limits for pharmaceutical active ingredients.

American Industrial Hygiene Association journal·1996
Same author

A collaborative evaluation of seven alternatives to the Draize eye irritation test using pharmaceutical intermediates.

Fundamental and applied toxicology : official journal of the Society of Toxicology·1995
Same author

Setting health-based residue limits for contaminants in pharmaceuticals and medical devices.

Quality assurance (San Diego, Calif.)·1992
Same journal

Mental health issues: ethical considerations.

Occupational medicine (Philadelphia, Pa.)·2002
Same journal

Ethics in the locker room: the challenges for team physicians.

Occupational medicine (Philadelphia, Pa.)·2002
Same journal

Ethical issues in worker productivity.

Occupational medicine (Philadelphia, Pa.)·2002
Same journal

Protecting posterity: the occupational physician's ethical and legal obligations to pregnant workers.

Occupational medicine (Philadelphia, Pa.)·2002
Same journal

Genetic testing: ethical implications in the workplace.

Occupational medicine (Philadelphia, Pa.)·2002
Same journal

Ethical issues in occupational disease outbreak investigations.

Occupational medicine (Philadelphia, Pa.)·2002
See all related articles

Pharmaceutical active ingredients can pose risks to employees. This chapter reviews the history and process of setting occupational exposure limits to ensure worker safety.

Area of Science:

  • Pharmaceutical industry
  • Occupational health
  • Toxicology

Background:

  • Active pharmaceutical ingredients (APIs) are designed to elicit biological responses.
  • Inadequate control of APIs can lead to significant occupational health risks for employees.
  • The pharmaceutical sector requires stringent safety protocols for handling potent compounds.

Purpose of the Study:

  • To provide a historical perspective on the necessity of occupational exposure limits (OELs).
  • To offer a comprehensive overview of the methodologies and considerations involved in setting OELs.
  • To highlight the importance of OELs in mitigating risks associated with pharmaceutical manufacturing.

Main Methods:

  • Historical review of occupational health regulations and guidelines.

Related Experiment Videos

  • Analysis of the scientific basis and data required for OEL derivation.
  • Examination of the regulatory and administrative processes for implementing OELs.

    • Main Results:

    • Established the critical need for OELs due to the inherent biological activity of pharmaceutical compounds.
    • Detailed the evolution of OELs from early concepts to current scientific approaches.
    • Outlined the multi-faceted process of OEL setting, involving toxicological data, risk assessment, and expert judgment.

    Conclusions:

    • Occupational exposure limits are essential for protecting pharmaceutical workers from hazardous active ingredients.
    • The process of setting OELs is complex, requiring a thorough understanding of toxicology and risk management.
    • Continuous evaluation and adherence to OELs are vital for maintaining a safe working environment in the pharmaceutical industry.